According to 'The PharmaLetter' Sanegene Bio has raised more than $110 million in a series B round to move its RNAi programs toward registration studies and broaden development across metabolic, cardiovascular and autoimmune diseases. The financing comes as global RNA-based medicines gain momentum and investors show renewed confidence in advanced delivery platforms.

The round was led by an unnamed industrial investor, joined by an international sovereign fund, China Biopharma, Legend Capital, and others. Eli Lilly (NYSE: LLY) made a strategic investment, while Hillhouse, Qiming and others also returned to support the company's next phase.